Bright Minds Biosciences (DRUG) EBITDA (2023 - 2024)

Bright Minds Biosciences (DRUG) posted EBITDA of $32422.2 for Q4 2024, down 79.37% on a QoQ basis from $157133.8 in Q2 2024, and up 102.62% year-over-year from $16001.4 in Q1 2024.

Bright Minds Biosciences (DRUG) EBITDA (2023 - 2024) Analysis & Trends

Bright Minds Biosciences' EBITDA history runs 2 years deep, the most recent figure standing at $32422.2 for Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -27.75 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 249.90 Mn
4 NuCana 279.75 Bn 279.75 Bn - -3.72 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 1.14 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 642.90 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -32.68 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 493.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -445.22 Mn
10 Bright Minds Biosciences 498.53 Mn 498.53 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 32,422.24
Jun 30, 2024 157,133.80
Dec 31, 2023 -1.24 Mn
Jun 30, 2023 -1.09 Mn